The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Tolerability and toxicity profile of chemotherapy with oxaliplatin in combination with infusional fluorouracil (FOLFOX) and capecitabine (XELOX) in a community oncology setting.
Raimundas Galiauskas
No relevant relationships to disclose
Edel Hassett
No relevant relationships to disclose
Kate Murphy
No relevant relationships to disclose
Donna Spillane
No relevant relationships to disclose
Gul Ahmed
No relevant relationships to disclose
Brian Richard Bird
No relevant relationships to disclose
Conleth G. Murphy
No relevant relationships to disclose